SCHEMBL12326823

SCHEMBL12326823

Cc1cc(C#N)cc(C(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
CYP2A6 P11509 1/20 0.38
VEGFA P15692 1/20 0.37
SOS1 Q07889 2/20 0.34
TTR P02766 2/20 0.34
ALB P02768 2/20 0.34
GRM5 P41594 3/20 0.33
XDH P47989 1/20 0.33
EPAS1 Q99814 1/20 0.33
VCAM1 P19320 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
KCNH2 Q12809 1/20 0.31
MGLL Q99685 1/20 0.31
APP P05067 1/20 0.31
BACE1 P56817 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
CXCR2 P25025 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890750 0.84 VCAM1 (0.38) TTRALBEPAS1VCAM1CYP11B1
SCHEMBL10204233 0.81 ALDH1A1 (0.39) ALDH1A1CYP2A6SOS1TTRALB
SCHEMBL29945753 0.78 ALDH1A1 (0.37) ALDH1A1CYP2A6SOS1TTRALB
SCHEMBL7358313 0.78 ALDH1A1 (0.37) ALDH1A1CYP2A6SOS1TTRALB
SCHEMBL16955395 0.78 ALDH1A1 (0.37) ALDH1A1CYP2A6SOS1TTRALB
SCHEMBL23526347 0.78 ALDH1A1 (0.37) ALDH1A1CYP2A6SOS1TTRALB
SCHEMBL29639654 0.77 EPAS1 (0.38) VEGFAGRM5EPAS1CYP11B1CYP11B2
SCHEMBL1890331 0.77 EPAS1 (0.38) VEGFAGRM5EPAS1CYP11B1CYP11B2
SCHEMBL15270426 0.77 ALDH1A1 (0.40) ALDH1A1
SCHEMBL1004620 0.77 ALDH1A1 (0.52) ALDH1A1CYP2A6TTRALBGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935246-B1 ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2018-07-25 EP disclosed
US-20160016915-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC. 2016-01-21 US disclosed
US-9029384-B2 Phosphatidylinositol 3-kinase inhibitors Gilead Calistoga, LLC. (US) 2015-05-12 US disclosed
US-20140179718-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2014-06-26 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179718-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PIK3R5, PIK3CA, PIK3R4 ALDH1A1 3794/4885CYP2A6 2307/4885VEGFA 3445/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 ALDH1A1 1380/4885CYP2A6 3755/4885VEGFA 4744/4885
US-20160016915-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PIK3R5, PIK3CA, PIK3R4 ALDH1A1 3794/4885CYP2A6 2307/4885VEGFA 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.